Fitness
GLP-1 weight loss costs muscle. In the first real trial, lifting weights stopped it
By Matthew Spencer
Published · Updated

The short answer: If you are losing weight on a GLP-1 drug like Mounjaro, Ozempic or Wegovy, some of the weight you lose is muscle, not just fat.
The first randomized trial to test the fix was published today in Nature Medicine, and the result is clear: people who lifted weights three times a week while taking tirzepatide kept more lean tissue and actually got stronger over 40 weeks. People who took the drug without training lost the same amount of weight but ended up weaker.
What the trial did
The T-REx trial, run by researchers at the University of Western Australia, followed 120 men and post-menopausal women aged 50 to 70. All were obese, or overweight with a weight-related health issue, none had type 2 diabetes, and all were prescribed tirzepatide (sold as Mounjaro or Zepbound) for weight management. Most tolerated dose increases up to 15 mg weekly.
Half were randomized to supervised resistance training three times a week; the other half continued their usual activities. Everyone received the same general advice on hydration, protein and fibre. The trial ran for 40 weeks, and adherence to the training program was 91%.
What it found
Both groups lost essentially the same weight: about 22.6 kg on the drug alone and 22.3 kg with training. Fat loss was also similar, around 17 to 18 kg. The difference was in what else was lost, and in strength.
The drug-only group lost 4.67 kg of lean soft tissue mass; the training group lost 3.57 kg, roughly a kilogram less. Strength told the sharper story. On tirzepatide alone, bench press, lat pulldown and knee extension strength all fell by about 4 to 4.5 kg.
With training, those same measures rose by about 4.7, 8.6 and 5.9 kg. In plain terms: the scale showed the same result, but one group ended the year weaker and the other stronger.
Why this matters
Losing some lean mass is part of any significant weight loss, whatever the method. What makes GLP-1 drugs different is the scale: these medicines routinely produce 20 to 25% reductions in body weight, and earlier studies using body scans found that 11 to 14% of lean soft tissue can disappear along the way.
Lean tissue is not all muscle - it includes water, organs and bone - but muscle is a large share of it, and muscle is what keeps you strong, stable and independent as you age.
Muscle loss is the mechanism behind sarcopenia and frailty in older adults, which is why researchers have been asking whether rapid GLP-1 weight loss trades one health problem for another, especially in people over 50.
What this trial cannot tell you
One trial is one trial. The participants were 50 to 70, so the results do not directly prove the same effect in younger adults. The drug tested was tirzepatide; whether the same training benefit applies to semaglutide (Ozempic, Wegovy) is plausible but unproven here.
Lean soft tissue measured by body scan is not a pure muscle measurement. And 40 weeks is meaningful but not a lifetime - the trial does not answer what happens when people stop the drug or stop training.
It also cannot say whether the extra preserved lean mass prevents falls or fractures years later, though the strength gains point in the right direction.
The useful takeaway
If you are on a GLP-1 medicine, or considering one, resistance training two to three times a week is the only add-on with randomized-trial evidence for protecting your muscle and strength, and this trial suggests it works without slowing weight loss. Protein intake matters too, and everyone in the trial received advice on it.
If you are new to lifting, over 50, or managing a health condition, get clearance from your doctor first and consider a supervised start - which is exactly how the trial's participants trained. This article reports research findings; it is not medical advice.
This is news reporting and not medical advice.